Related Experiment Videos
Bronchiolitis in children
H B Panitch1, C W Callahan, D V Schidlow
1Department of Pediatrics, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania.
Insights
Bronchiolitis, a common infant respiratory infection caused by RSV, can lead to long-term issues. Ribavirin shows promise in treating RSV bronchiolitis and preventing lasting airway problems.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pulmonology
Background:
- Bronchiolitis is an acute airway inflammation in infants, commonly caused by Respiratory Syncytial Virus (RSV).
- It presents as a lower respiratory tract infection with airway obstruction, typically lasting one week.
- Severe cases or those with underlying conditions can result in significant morbidity and long-term sequelae like Persistent Bronchial Hyperresponsiveness (PBAR) and Obstructive Bronchitis (OB).
Purpose of the Study:
- To review the pathogenesis of bronchiolitis, focusing on the role of RSV and host immune response.
- To evaluate current and potential therapeutic strategies for managing bronchiolitis.
- To explore the efficacy of antiviral agents, specifically ribavirin, in treating RSV-induced bronchiolitis and preventing long-term complications.
Main Methods:
- Literature review of studies on bronchiolitis pathogenesis and treatment.
- Analysis of clinical data regarding the effectiveness of various therapeutic modalities.
- Examination of research on the immunomodulatory effects of antiviral agents like ribavirin.
Main Results:
- RSV infection directly damages airways, with an exaggerated immune response potentially contributing to obstruction.
- Oxygen and fluid resuscitation are standard care; corticosteroids are not supported, while bronchodilators show benefit in some patients.
- Ribavirin demonstrates potential as an antiviral therapy for bronchiolitis and may mitigate immune responses to prevent sequelae.
Conclusions:
- Bronchiolitis management requires supportive care, with specific treatments like bronchodilators and ribavirin showing promise.
- Understanding the interplay between viral damage and immune response is crucial for preventing long-term airway issues.
- Ribavirin offers a potential therapeutic avenue for both acute RSV infection and the prevention of chronic sequelae in bronchiolitis.
Abstract:
Bronchiolitis is an acute inflammation of the airways. In infancy, it usually results from viral infection, with RSV the most common agent. The clinical syndrome is characterized by symptoms of lower respiratory tract infection and obstruction. In most patients, the duration of illness is 1 week, but bronchiolitis can cause serious morbidity in patients with pre-existing cardiopulmonary disease. In addition, patients may be left with serious sequelae, including PBAR and OB. RSV causes direct damage to airways, but an exaggerated host immune response may contribute to the pathogenesis of airway obstruction in bronchiolitis. The mainstays of therapy include oxygen supplementation and fluid resuscitation, and other modalities remain controversial. There are no studies to support the use of corticosteroids alone in the treatment of bronchiolitis, but several recent reports demonstrate the value of bronchodilator therapy in some patients. Antiviral agents such as ribavirin show great promise in a therapy for bronchiolitis. In addition, ribavirin may modify some aspects of the immune response during acute infection with RSV, and therefore may play a role in the prevention of long-term sequelae.